Literature DB >> 2535698

Dynamics of hepatic connective tissue matrix constituents during murine Schistosoma mansoni infection.

S el-Meneza1, G R Olds, T F Kresina, A A Mahmoud.   

Abstract

Hepatic fibrosis is the major clinical sequela of infection with the helminth Schistosoma mansoni. However, little is known regarding its dynamics and regulation in schistosomiasis. The present study presents the dynamics of deposition and resorption of two major extracellular matrix components of fibrosis, glycosaminoglycans and collagens, during the course of experimental S. mansoni infection. Early in infection (6 weeks), glycosaminoglycan biosynthesis was markedly elevated, as was collagen biosynthesis. This led to significant accumulations of these two molecules at a glycosaminoglycan/collagen ratio similar to that observed in livers of uninfected mice (uronic acid/hydroxyproline ratio of 1.10 at 6 weeks compared to normal value of 1.25). During maximal hepatic fibrosis (12 to 18 weeks), both collagen and glycosaminoglycan biosynthesis continued to increase but the extracellular matrix shifted to a lower glycosaminoglycan/collagen ratio of 0.42, suggesting enhanced glycosaminoglycan breakdown. In addition, during this acute stage of infection, Type I collagen was the predominant isotype synthesized, whereas total collagenolytic activity degrading Type I collagen was maximal. During chronic infection, a decrease in the content of both hepatic glycosaminoglycans and collagens were noted, with a glycosaminoglycan/collagen ratio of 0.63. Decreased glycosaminoglycan content paralleled diminished biosynthetic rates. On the other hand, an over 50% reduction in collagen content (from 18 to 24 weeks) appeared not to result from diminished biosynthesis but from a switch in the predominant collagen isotype synthesized (from Type I to Type III), matched by an enhanced constitutive collagenolytic activity directed toward this type of collagen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535698     DOI: 10.1002/hep.1840090108

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice.

Authors:  Omaima Mohammed Abou-Shady; Soheir Sayed Mohammed; Samar Sayed Attia; Hebat-Allah Salah Yusuf; Dina Omar Helmy
Journal:  J Parasit Dis       Date:  2014-06-01

2.  Identification of cytokeratin 18 as a biomarker of mouse and human hepatosplenic schistosomiasis.

Authors:  Bhagyashree Manivannan; Pisana Rawson; T William Jordan; Diana M S Karanja; Pauline N M Mwinzi; William Evan Secor; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

3.  Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension.

Authors:  S K Sarin; R J Groszmann; P G Mosca; M Rojkind; M J Stadecker; R Bhatnagar; A Reuben; Y Dayal
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

4.  Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis.

Authors:  Naglaa M El-Lakkany; Olfat A Hammam; Walaa H El-Maadawy; Afkar A Badawy; Afaf A Ain-Shoka; Fatma A Ebeid
Journal:  Parasit Vectors       Date:  2012-01-11       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.